Myocardial Ischemia – Pipeline Review including key players Angionetics , Bayer AG, Cellmid

Myocardial Ischemia – Pipeline Review including key players Angionetics , Bayer AG, Cellmid

HTF Market Report released a new research document of 66 pages on industry titled as ‘Myocardial Ischemia – Pipeline Review, H2 2017’ with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis and important players/vendors such as Angionetics Inc,Bayer AG,Cellmid Ltd,CohBar Inc,Lixte Biotechnology Holdings Inc,NoNO Inc,Omniox Inc The report will help you gain market insights, future trends and growth prospects for forecast period of 2017-22


Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Ischemia – Pipeline Review, H2 2017, provides an overview of the Myocardial Ischemia (Cardiovascular) pipeline landscape.


Request a sample report @


Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm and severe illnesses. The factors that may increase the risk of developing myocardial ischemia include tobacco, diabetes, high blood pressure, high blood cholesterol or triglyceride levels, lack of physical activity, obesity and family history.


Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Myocardial Ischemia – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myocardial Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.


The Myocardial Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Get Customization in the Report, Enquire Now @


Myocardial Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.



– The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Ischemia (Cardiovascular).

– The pipeline guide reviews pipeline therapeutics for Myocardial Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Myocardial Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Myocardial Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Ischemia (Cardiovascular)


Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Myocardial Ischemia (Cardiovascular).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Myocardial Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Companies Mentioned in the Report

Angionetics Inc

Bayer AG

Cellmid Ltd

CohBar Inc

Lixte Biotechnology Holdings Inc

NoNO Inc

Omniox Inc

Pathfinder Cell Therapy Inc


Buy this report @


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Myocardial Ischemia – Overview 7

Myocardial Ischemia – Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Myocardial Ischemia – Therapeutics Assessment 13

Assessment by Target 13




View Detailed Table of Content @


Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.


Contact Us:

CRAIG FRANCIS (PR & Marketing Manager)

[email protected]

Ph: +1 (206) 317 1218


Article written by Craig Francis

HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.